Industry News

The National Institutes of Health is giving a La Jolla scientist a record $120 million to help medicine make a historic shift to treating patients based on their specific genetic makeup, lifestyle and environment. Dr. Eric Topol will co-lead the effort to enroll and engage 1 million A

Officials from the French National Blood Service visited the Blood Bank of Delmarva last month and toured their facility in Newark. French and U.S. Officials at the Blood Bank of Delmarva (Photo: Blood Bank of Delmarva) The visit was part of a day long meeting between leaders of Ameri

LifeServe Blood Center is changing its donor eligibility policy next month to comply with new FDA guidelines on blood donations from gay and bisexual men. The FDA revised its policy last December from a complete ban to accepting donations from men who haven’t had sex with men in the p

A coalition of liberal interest groups and 130 members of Congress are calling on the Food and Drug Administration (FDA) to change its current policy governing blood and plasma donations from men who have sex with men (MSM). Under the current policy, which was approved in December 201

Researchers, led by Carnegie Mellon University President Subra Suresh and MIT Principal Research Scientist Ming Dao, have created a new computer model that shows how tiny slits in the spleen prevent old, diseased or misshapen red blood cells from re-entering the bloodstream. Members o

Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene Pioneering Public-Private Cancer Initiative with Unified Leadership Committed to Changing the Course of Cancer Care NEW YORK–(BUSINESS WIRE)–Today, The Abramson Cancer Center at t

CRISPR, the genome-editing technology that has taken biomedical science by storm, is finally nearing human trials. On June 21, an advisory committee at the US National Institutes of Health (NIH) approved a proposal to use CRISPR–Cas9 to help augment cancer therapies that rely on enlis

PCT has expanded its relationship with Kiadis Pharma (Euronext Amsterdam and Brussels: KDS) (“Kiadis”), by entering into an agreement for the manufacturing of cell therapy product for United States and Canada clinical trial sites for a Phase 3 trial of Kiadis’ lead product, ATIR101™,

The U.S. Food and Drug Administration (FDA) has approved the first clinical trial of a Zika vaccine involving humans. Inovio Pharmaceuticals of Pennsylvania and GeneOne Life Science of South Korea joined forces to develop the drug named GLS-5700 and researchers will be able to announc